¡°	generic clopidogrel bisulfate product	5.5071608517788935
	dextrorotatory enantiomer	5.430757685027281
	disclose bisulfate	5.393317626936117
	bisulfate salt limitation	4.201015328337092
¡°	Plavix	3.2081229763931636
	single enantiomer	2.788185051060139
	dextrorotatory levorotatory enantiomer	2.529281623553884
	compound MATTPCA	1.561517036670052
	alpha-5	1.2390909549553513
	BMS	1.2381851863905222
	expert	1.0077395356852392
	racemate free base	0.7471506659257829
	levorotatory isomer	0.6931241003845733
	hydrobromide salt	0.6841769751696619
	Schaumann	0.6221788842078882
	Stereochemistry	0.6197722510987648
	2-chlorophenyl)-acetate	0.6197722510987648
	Methyl	0.6197722510987648
	C.C.P.A	0.6197722510987648
	irreparable harm	0.577766128450369
	settlement negotiation	0.42386768942845715
	stroke	0.3775732214613228
	thrombotic event	0.3654050451135929
	Petering	0.3614309287256547
	Clopidogrel	0.35750102121859484
	hydrochloride salt	0.3453551918246273
	salt formation	0.3366014123210842
	racemic mixture	0.3319127453284725
	unclean hand defense	0.31997045966322657
	Merits	0.3098861255493824
	6-a	0.3098861255493824
	plane polarize light	0.2745198105326392
	dextro rotatory isomer	0.27334419981071234
	levo rotatory isomer	0.27334419981071234
	Hydrogen sulfate	0.27317836696796505
	stereochemistry	0.24921097184091695
	certain compatible salt	0.24916791891083712
	additional testimony	0.24843865979950305
	preliminary injunction	0.2415853066639851
	injunction bond	0.24113350408849932
	generic launch.2	0.22113717268857924
	potentially acceptable salt	0.22087950047852292
	anticipation defense	0.21696103806752207
	anticipation challenge	0.21308523530302587
	first settlement agreement	0.21087553350514232
	enforceability	0.21026968721282635
	schaumann warrant reversal	0.209824550801769
	preferred salt	0.2085194479241129
	addition salt	0.20809665261478738
	genentech	0.2068740492721617
	either FTC	0.20659319191559697
	recall	0.20041566887916704
	platelet aggregation	0.20016110121272732
	a. Likelihood	0.17919507613689056
	hardship	0.16846402641201091
	enantiomers.1 mixture	0.16815298604505402
	substantial merit.4 determination	0.1554610270884751
	regulatory approval	0.15320817398253167
	stereoisomer	0.1501757749722535
	preliminary injunctive relief	0.1439979029251702
	non superimposable mirror image	0.1374878825538582
	Example	0.13365932183960352
	different spatial arrangement	0.133066619464505
	Amazon.com	0.12639421091379408
	Success	0.12325925082488345
	least fifty different pharmaceutically acceptable salt	0.11436219296801618
	aforementioned agreement	0.10758643012800827
	lache	0.1034748859222723
	pharmaceutically acceptable mineral	0.09945770836970401
	specific preference	0.09560429632801508
	disclose preference	0.09554122315349717
	Tate Access Floors	0.09175818391001062
	regulatory denial	0.09019726813211264
	asymmetrical carbon atom	0.08386451962532224
	ANDA	0.07543270311799
	three dimensional spatial arrangement	0.07526745981064474
	Interface Architectural Res	0.07473521390946537
	variable substituent	0.07156955501375149
	impermissible hindsight drive dissection recombination analysis	0.07124004143184258
	preliminary matter	0.0672517439685724
	generalize understanding	0.0638534938259286
	organic acid	0.059797042964884806
	distributor	0.05898211039132202
	second agreement	0.05753627714183945
	Customs Patent Appeals	0.05729344911261567
	provision	0.05491269010556529
	free base methyl	0.05487715282305388
	broad genus	0.05195773012382219
	genus specie anticipation	0.050262195236798764
	chemical substituent	0.045744159587467026
	molecule constituent atom	0.03874329109983875
	opposition	0.03809421017981974
	undue experimentation	0.03677225523972208
	injunction impact	0.03661970730848991
	May agreement	0.03617737470195273
	expedite briefing schedule	0.03605184117512375
	Bristol Myers Squibb	0.035164443218320435
	approximately twenty compound	0.03459538882036428
	obviousness type double patenting	0.03387465110743915
	limited class	0.03367498304934154
	Paragraph IV certification	0.03304309469580484
	narrow class	0.032459976230461825
	FDA approval	0.032181660879756345
	small class	0.03212162364603474
	deferential standard	0.02945796975556485
	Rockwell Int'l Corp.	0.02945356080572016
	heart attack	0.025217644665348246
	narrow generic formula	0.02465095484849272
	generic version	0.022708859708782503
	specie compound	0.022427752632181733
	specific chemical compound	0.02128938535100428
	balance	0.02077912818063297
	substantial separation	0.019627598750835116
	unpredictable exercise	0.01921228164193484
	specific compound	0.019177120127658615
	Barnesandnoble.com Inc.	0.017474117996031522
	optical activity	0.01703864382343592
	agent active ingredient	0.014297622787054228
	Federal Trade Commission	0.013999784389144426
	Hatch Waxman Act	0.01325831535294401
	single variable	0.012711953771718534
	obviousness type double invalidity defense	0.012463220842098213
	Abbreviated New Drug Application	0.011723547565969298
	thirty month stay	0.009938054197736388
	sound discretion	0.00898394351953717
	clear pattern	0.00792913002174227
	Lourie	0.007861887944669656
	New York	0.0076192599202839556
	inequitable conduct	0.007603362454090771
	alleged anticipation	0.007141554571422718
	member	0.00705518774931857
	a. anticipation	0.0069564675228019224
	U.S. Food Drug Administration	0.006914235875551069
	public interest	0.006887614186018576
	August	0.0066093338550724185
	intent	0.005970647134256008
	Southern District	0.005933129499308864
	equal amount	0.005857617121496753
	formulation	0.005834488776630378
	careful consideration	0.005803834570957025
	Opinion	0.005506878693251282
	inter alia	0.005434690181788767
	predecessor court	0.004372287427623299
	anticipation analysis	0.004351123902289818
	six month supply	0.004182134091342182
	Examiner	0.00348190812993098
	reasonable likelihood	0.0031347662823464177
	every stage	0.0030172822374120037
	two main argument	0.0027886135123220504
	success	0.0027758691532309247
	two miss limitation	0.0025340351100369947
	issuance	0.002436603058401191
	November	0.002395242084106368
	prior art mandate	0.002371523978999615
	time frame	0.0021872036096709613
	two day evidentiary hearing	0.0019626582797773865
	July	0.0016926151884950657
	relevant factor	0.0016320884432944503
	patentee entry	0.0016287079964134434
	oral argument	0.0016271940707182474
	accordance	0.0016183241605006791
	January	0.0013219595883091526
	another litigation	0.0013216669559013333
	March	0.0012581809112507602
	plain language	0.001254063504917327
	obvious distinction	0.0010922444044800931
	appellant	0.0010842168847111412
	state attorney general	0.001040570341302536
	remain three factor	0.0008430801815216607
	establish four factor test	0.0008205665256416673
	follow key limitation	0.0007978762180169598
	contrast	0.0007299287142357639
	substantial question	0.000687899728719213
	express disclosure	0.0006323627506538825
	September	0.000629320723016235
	burden	0.0005378108101230274
	control precedent	0.00047947660155105967
	October	0.0004674169524408642
	patentee right	0.0004365017634182277
	patentee request	0.0003631787723954237
	second inquiry	0.00022867300064417987
	respect	0.00020749262046337508
	competitor obviousness challenge	0.0001964432935357334
	competitor challenge	0.0001656474352921372
	response	0.00015821456569002724
	holding	0.0001221204373063099
	every limitation	0.00010972873871195018
	clearly erroneous factual finding	0.00010540810215944688
	patentee favor	6.659287291061022e-05
	ordinary skill	6.587420514815136e-05
	move party	6.5381011138386e-05
	background	5.946643036187893e-05
	several reason	5.786944048393096e-05
	clear statement	3.687100253461971e-05
	district court ruling	3.563140708089708e-05
	regard	3.5035262841916715e-05
	accuse product infringe	2.9551980435195164e-05
	reject	2.7713566624379213e-05
	Ltd.	2.7365168686851586e-05
	jurisdiction	2.5219832749266727e-05
	neither party	2.5169093368512143e-05
	first element	2.1034480990839252e-05
	view	2.0042088774401406e-05
	clear error	1.8019889693132746e-05
	issue de novo	1.5588480552676096e-05
	single prior art reference	1.3471140544773423e-05
	trial	1.3235692719261345e-05
	two ground	1.0461577103777456e-05
	emphasis	1.0227935699727775e-05
	prosecution	1.002837507334721e-05
	order	9.81128030231381e-06
	Claim	9.488435614477317e-06
	fact finding	7.495188375892581e-06
	district court decision	3.270115703634467e-06
	Idaho	1.9316850700926823e-06
	conclusion	1.682160739335314e-06
	district court grant	1.515600777207391e-06
	present case	3.2774686729267796e-07
	support	1.9411437806222858e-07
	infringement action	9.102746094877591e-08
	law	4.759276614650243e-08
	judgment	2.400068869819731e-09
	Court	0.0
	United States	0.0
